metformin
Phase 2/3UNKNOWN 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fatty Liver
Conditions
Fatty Liver
Trial Timeline
Nov 1, 2004 → Jun 1, 2008
NCT ID
NCT00303537About metformin
metformin is a phase 2/3 stage product being developed by Merck for Fatty Liver. The current trial status is unknown. This product is registered under clinical trial identifier NCT00303537. Target conditions include Fatty Liver.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04500678 | Phase 2/3 | UNKNOWN |
| NCT02017561 | Phase 2 | Completed |
| NCT02710448 | Phase 2 | Completed |
| NCT00390273 | Phase 1/2 | Completed |
| NCT00134303 | Approved | Completed |
| NCT00303537 | Phase 2/3 | UNKNOWN |
Competing Products
20 competing products in Fatty Liver
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lanifibranor | Inventiva | Phase 2 | 47 |
| Low Dose REN001 + High Dose REN001 | OnKure Therapeutics | Phase 1 | 25 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| placebo + Omega-3 carboxylic acids + Dapagliflozin + Placebo | AstraZeneca | Phase 2 | 52 |
| AZ compound | AstraZeneca | Phase 2 | 52 |
| Placebo + Omega-3 carboxylic acid + Fenofibrate 200mg + Placebo | AstraZeneca | Phase 2 | 52 |
| AZD7503 Intervention | AstraZeneca | Phase 1 | 33 |
| Efinopegdutide + Semaglutide + Placebo | Merck | Phase 2 | 52 |
| MK-4074 200 mg + Placebo for MK-4074 + Pioglitazone hydrochloride 30 mg + Placebo for pioglitazone hydrochloride | Merck | Phase 1 | 33 |
| Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mL | Merck | Phase 2 | 52 |
| LYS006 + Tropifexor | Novartis | Phase 2 | 52 |
| LJN452 | Novartis | Phase 1 | 33 |
| LCQ908 + placebo | Novartis | Phase 2 | 52 |
| Orlistat (Xenical) | Roche | Approved | 85 |
| Xenical, Pegasys, Copegus | Roche | Approved | 85 |
| Placebo + RO5093151 | Roche | Phase 1 | 33 |
| AMG 609 + Placebo | Amgen | Phase 1 | 32 |
| Glucagon | Novo Nordisk | Pre-clinical | 22 |
| Blood samples | Novo Nordisk | Pre-clinical | 22 |
| NNC0194-0499 + NNC0194-0499 + NC0194-0499 | Novo Nordisk | Phase 1 | 32 |